Retifanlimab联合铂类化疗一线治疗转移性非小细胞肺癌的III期研究
POD1UM-304是一项III期多区域双盲随机安慰剂对照研究,纳入583例初治IV期非鳞或鳞状转移性NSCLC患者,2:1随机接受retifanlimab或安慰剂联合铂类化疗。
要点
- Retifanlimab联合铂类化疗较安慰剂显著改善初治转移性NSCLC的总生存期。
- 联合组严重不良事件、≥3级不良事件及导致停药的事件发生率均高于对照组。
- 该方案可能成为鳞状或非鳞状转移性NSCLC患者一线治疗的新选择。
核心结论
- 在铂类化疗基础上加用retifanlimab较安慰剂显著延长了初治转移性非鳞或鳞状NSCLC患者的总生存期。
- Retifanlimab联合化疗的安全性特征与既往PD-1/PD-L1抑制剂联合化疗方案相似。
研究设计与样本
- POD1UM-304为III期、多区域、安慰剂对照、双盲、随机研究,在16个国家约124家医院和私人临床中心开展。
- 纳入年龄≥18岁、ECOG PS 0或1、无既往转移性NSCLC系统治疗的IV期鳞状或非鳞状NSCLC患者。
- 患者按2:1随机接受retifanlimab 375 mg或安慰剂(每21天周期第1天静脉给药)联合基于组织学的标准铂类化疗,最多35个周期。
- 随机化按PD-L1表达肿瘤比例评分、地理区域和主要肿瘤组织学分层。
- 主要终点为总生存期,在全分析集中分析;安全性在所有接受至少一剂研究药物的随机患者中评估。
主要发现
- 2020年9月11日至2023年3月14日期间,1388例患者接受资格评估,583例随机分配至retifanlimab联合化疗组(n=391)或安慰剂联合化疗组(n=192)。
- 381例(65%)为非鳞状NSCLC,202例(35%)为鳞状NSCLC;467例(80%)为男性,116例(20%)为女性;中位年龄64岁(IQR 58-68)。
- Retifanlimab联合化疗组严重治疗中出现的不良事件发生率更高(158/389 [41%] vs 57/190 [30%]),≥3级事件更高(238 [61%] vs 103 [54%]),导致剂量延迟(169 [43%] vs 67 [35%])或停药(33 [8%] vs 9 [5%])的事件也更高。
- 致命性COVID-19相关治疗中出现的不良事件比例两组相似(4 [1%] vs 5 [3%])。
关键数值与推荐
- Retifanlimab联合化疗组严重治疗中出现的不良事件158/389(41%),安慰剂联合化疗组57/190(30%)。
- Retifanlimab联合化疗组≥3级治疗中出现的不良事件238/389(61%),安慰剂联合化疗组103/190(54%)。
临床怎么用
- 对于初治的转移性非鳞或鳞状NSCLC患者,可考虑在铂类化疗基础上联合retifanlimab以改善总生存。
- 使用retifanlimab联合化疗时需注意严重不良事件和≥3级不良事件发生率高于单纯化疗,应加强监测。
局限性
- 研究未报告无进展生存期、客观缓解率等其他疗效终点的数据。
- 研究未报告生活质量或症状改善相关结果。
- 研究未提供亚组分析的详细数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Checkpoint inhibitors, including combinations with standard-of-care chemotherapy, have shown survival benefit in patients with metastatic non-small-cell lung cancer (NSCLC); however, access to these drugs varies. We aimed to evaluate the efficacy of the PD-1 inhibitor retifanlimab plus platinum-based chemotherapy as first-line treatment for non-squamous or squamous metastatic NSCLC. METHODS: POD1UM-304 was a phase 3, multiregional, placebo-controlled, double-blind, randomised study conducted in approximately 124 hospitals and private clinical centres in 16 countries. Male and female adults aged 18 years or older with squamous or non-squamous stage IV NSCLC (staging by American Joint Committee on Cancer version 8) with Eastern Cooperative Oncology Group performance status 0 or 1 and no previous systemic therapy for metastatic NSCLC were eligible. Patients were randomly assigned (2:1) using interactive response technology to receive intravenous retifanlimab 375 mg or matching placebo on day 1 of each 21-day cycle plus standard platinum-based chemotherapy according to tumour histology for up to 2 years. Patients with non-squamous NSCLC received pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 on day 1 for four cycles, or carboplatin area under the curve (AUC) 5 on day 1 for four cycles, followed by pemetrexed 500 mg/m2 on day 1 of each subsequent 21-day cycle, all administered intravenously, until disease progression or unacceptable toxicity. Patients with squamous NSCLC received intravenous carboplatin AUC 6 plus intravenous paclitaxel 200 mg/m2 on day 1 for four cycles or intravenous nab-paclitaxel 100 mg/m2 on days 1, 8, and 15 for four cycles. Treatment with retifanlimab or placebo was given for up to 35 cycles, unless there was disease progression, unacceptable toxicity, or withdrawal of consent. Randomisation was stratified by PD-L1 expression tumour proportion score, geographical region, and predominant tumour histology. The primary endpoint was overall survival, defined as time from randomisation until death due to any cause, analysed in the full analysis set. Safety was evaluated in all randomly assigned patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT04205812) and is active but no longer enrolling. FINDINGS: Between Sept 11, 2020, and March 14, 2023, 1388 patients were assessed for eligibility, 583 of whom were randomly assigned to retifanlimab plus chemotherapy (n=391) or placebo plus chemotherapy (n=192). 381 (65%) patients had non-squamous NSCLC and 202 (35%) had squamous NSCLC; 467 (80%) patients were male and 116 (20%) were female. Median age was 64 years (IQR 58-68). Median overall survival was longer in the retifanlimab plus chemotherapy group than in the placebo plus chemotherapy group (18·1 months [95% CI 16·2-21·0] vs 13·4 months [11·0-16·7]; hazard ratio 0·75 [95% CI 0·60-0·93]; p=0·0042). Overall, higher incidences of treatment-emergent adverse events that were serious (158 [41%] of 389 vs 57 [30%] of 190), grade 3 or worse (238 [61%] vs 103 [54%]), or led to retifanlimab or placebo dose delay (169 [43%] vs 67 [35%]) or discontinuation (33 [8%] vs nine [5%]) were observed in the retifanlimab plus chemotherapy group than in the placebo plus chemotherapy group. The proportions of fatal COVID-19-related treatment-emergent adverse events were similar in the retifanlimab plus chemotherapy group and the placebo plus chemotherapy group (four [1%] vs five [3%]). INTERPRETATION: Retifanlimab improved overall survival compared with placebo when added to platinum-based chemotherapy, with a safety profile that is representative of previous PD-1 and PD-L1 inhibitor-chemotherapy combinations. Adding retifanlimab to first-line chemotherapy could be a potential treatment option for patients with squamous or non-squamous metastatic NSCLC. FUNDING: Incyte.
引用
- Lu S, Vynnychenko O, Kulyaba Y, et al. Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study. Lancet Respir Med. 2025. PMID: 40983066. doi:10.1016/S2213-2600(25)00209-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。